| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
We have investigated the effects of tumor suppression and the control of dissemination with EGFR/VEGF dual inhibitor, Vandetanib in glioma cells. Vandetanib indicated the suppression of tumor proliferation and invasion and induced apoptosis in rat C6 glioma cells using several in vitro studies. Same tendency was recognized in human glioblastoma cell lines, but significant suppression was not obtained in MGMT-positive human glioblastoma cell lines. We transfected MGMT siRNA into the MGMT-positive cell lines and performed same experiments. We could confirm the improvement of reactivity of Vandetanib treatment, but not obtain the significant results. It is necessary to do further reseach to perform the experiment with rat dissemination models.
|
